Inhaled ciprofloxacin promising in cystic fibrosis
This article was originally published in Scrip
Executive Summary
Aradigm's inhaled liposomal formulation of ciprofloxacin, given once daily, has been associated with reductions in sputum Pseudomonas aeruginosa in an open-label two-week trial in 21 patients with cystic fibrosis.